Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 96

1.

System-wide investigation of ErbB4 reveals 19 sites of Tyr phosphorylation that are unusually selective in their recruitment properties.

Kaushansky A, Gordus A, Budnik BA, Lane WS, Rush J, MacBeath G.

Chem Biol. 2008 Aug 25;15(8):808-17. doi: 10.1016/j.chembiol.2008.07.006.

2.

Phosphotyrosine interactome of the ErbB-receptor kinase family.

Schulze WX, Deng L, Mann M.

Mol Syst Biol. 2005;1:2005.0008. Epub 2005 May 25.

3.

The Q43L mutant of neuregulin 2β is a pan-ErbB receptor antagonist.

Wilson KJ, Mill CP, Gallo RM, Cameron EM, VanBrocklin H, Settleman J, Riese DJ.

Biochem J. 2012 Apr 1;443(1):133-44. doi: 10.1042/BJ20110921.

4.

ErbB2 and ErbB3 do not quantitatively modulate ligand-induced ErbB4 tyrosine phosphorylation.

Feroz K, Williams E, Riese DJ 2nd.

Cell Signal. 2002 Sep;14(9):793-8.

PMID:
12034361
5.

Neuregulin-1 only induces trans-phosphorylation between ErbB receptor heterodimer partners.

Li Z, Mei Y, Liu X, Zhou M.

Cell Signal. 2007 Mar;19(3):466-71. Epub 2006 Sep 15.

PMID:
16978839
6.

Quantitative Phosphoproteomics Analysis of ERBB3/ERBB4 Signaling.

Wandinger SK, Lahortiga I, Jacobs K, Klammer M, Jordan N, Elschenbroich S, Parade M, Jacoby E, Linders JT, Brehmer D, Cools J, Daub H.

PLoS One. 2016 Jan 8;11(1):e0146100. doi: 10.1371/journal.pone.0146100. eCollection 2016.

7.

Heregulin (HRG)-induced mitogenic signaling and cytotoxic activity of a HRG/PE40 ligand toxin in human breast cancer cells.

Fiddes RJ, Janes PW, Sanderson GM, Sivertsen SP, Sutherland RL, Daly RJ.

Cell Growth Differ. 1995 Dec;6(12):1567-77.

8.

Microbead arrays for the analysis of ErbB receptor tyrosine kinase activation and dimerization in breast cancer cells.

Khan IH, Zhao J, Ghosh P, Ziman M, Sweeney C, Kung HJ, Luciw PA.

Assay Drug Dev Technol. 2010 Feb;8(1):27-36. doi: 10.1089/adt.2009.0208.

9.

A quantitative protein interaction network for the ErbB receptors using protein microarrays.

Jones RB, Gordus A, Krall JA, MacBeath G.

Nature. 2006 Jan 12;439(7073):168-74. Epub 2005 Nov 6.

PMID:
16273093
10.

Compensatory ErbB3/c-Src signaling enhances carcinoma cell survival to ionizing radiation.

Contessa JN, Abell A, Mikkelsen RB, Valerie K, Schmidt-Ullrich RK.

Breast Cancer Res Treat. 2006 Jan;95(1):17-27.

11.

ErbB receptors mediate both migratory and proliferative activities in human melanocytes and melanoma cells.

Gordon-Thomson C, Jones J, Mason RS, Moore GP.

Melanoma Res. 2005 Feb;15(1):21-8.

PMID:
15714117
12.

Widespread expression of ErbB2, ErbB3 and ErbB4 in non-human primate brain.

Thompson M, Lauderdale S, Webster MJ, Chong VZ, McClintock B, Saunders R, Weickert CS.

Brain Res. 2007 Mar 30;1139:95-109. Epub 2007 Feb 5.

PMID:
17280647
13.

Negative constraints underlie the ErbB specificity of epidermal growth factor-like ligands.

van der Woning SP, van Rotterdam W, Nabuurs SB, Venselaar H, Jacobs-Oomen S, Wingens M, Vriend G, Stortelers C, van Zoelen EJ.

J Biol Chem. 2006 Dec 29;281(52):40033-40. Epub 2006 Oct 10.

16.

ErbB receptor-induced activation of stat transcription factors is mediated by Src tyrosine kinases.

Olayioye MA, Beuvink I, Horsch K, Daly JM, Hynes NE.

J Biol Chem. 1999 Jun 11;274(24):17209-18.

17.

Adenovirus-mediated overexpression of dominant negative epidermal growth factor receptor-CD533 as a gene therapeutic approach radiosensitizes human carcinoma and malignant glioma cells.

Lammering G, Lin PS, Contessa JN, Hampton JL, Valerie K, Schmidt-Ullrich RK.

Int J Radiat Oncol Biol Phys. 2001 Nov 1;51(3):775-84.

PMID:
11697324
18.

ErbB kinases and NDF signaling in human prostate cancer cells.

Grasso AW, Wen D, Miller CM, Rhim JS, Pretlow TG, Kung HJ.

Oncogene. 1997 Nov 27;15(22):2705-16.

19.

Comprehensive binary interaction mapping of SH2 domains via fluorescence polarization reveals novel functional diversification of ErbB receptors.

Hause RJ Jr, Leung KK, Barkinge JL, Ciaccio MF, Chuu CP, Jones RB.

PLoS One. 2012;7(9):e44471. doi: 10.1371/journal.pone.0044471. Epub 2012 Sep 4.

20.

Kinase activator-receiver preference in ErbB heterodimers is determined by intracellular regions and is not coupled to extracellular asymmetry.

Ward MD, Leahy DJ.

J Biol Chem. 2015 Jan 16;290(3):1570-9. doi: 10.1074/jbc.M114.612085. Epub 2014 Dec 2.

Supplemental Content

Support Center